Moxifloxacin Eberth

Moxifloxacin, the active ingredient in Moxifloxacin Eberth, is a fluoroquinolone antibiotic presented as an injection for intravenous use. It treats a range of serious bacterial infections in adult patients, including pneumonia, sinusitis, and complicated skin or intra‑abdominal infections.

GNH USA supplies Moxifloxacin Eberth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in various organ systems.

Community‑acquired bacterial pneumonia: effective eradication of susceptible pathogens causing lung infection. Acute bacterial sinusitis: rapid bacterial clearance in sinus cavities. Complicated skin and skin‑structure infections: treatment of severe dermal infections caused by susceptible organisms. Complicated intra‑abdominal infections: control of mixed bacterial flora in abdominal cavities. Acute exacerbations of chronic bronchitis: reduction of bacterial load during flare‑ups.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea - Headache - Dizziness or vertigo - Rash or mild skin irritation - Elevated liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendonitis, especially in the Achilles tendon - QT interval prolongation leading to cardiac arrhythmias - Severe hypersensitivity reactions (anaphylaxis, Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis - Hepatic failure or jaundice - Peripheral neuropathy

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for adverse events.

Renal impairment: adjust therapy and monitor renal function. Hepatic impairment: use with caution; monitor liver enzymes. QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. Elderly patients: increased susceptibility to tendon injury; advise caution. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Antacids or supplements containing aluminum, magnesium, calcium, or iron: reduce absorption. - Warfarin: may increase INR and bleeding risk. - Theophylline: increased plasma concentrations leading to toxicity. - Cyclosporine: elevated cyclosporine levels. - Amiodarone or other QT‑prolonging agents: heightened risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation. - Oral contraceptives: reduced effectiveness, consider backup method. - Diabetic agents (e.g., sulfonylureas): potential hypoglycemia. - Corticosteroids: increased risk of tendon rupture. - Rifampin: may reduce moxifloxacin plasma levels.